Nevro Corp. (NVRO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 47.59 |
| Open | 48.01 |
| Bid | 46.59 x 900 |
| Ask | 49.18 x 1400 |
| Day's Range | 47.17 - 49.49 |
| 52 Week Range | 39.41 - 169.81 |
| Volume | |
| Avg. Volume | 571,700 |
| Market Cap | 1.735B |
| Beta (5Y Monthly) | 1.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.90 |
| Earnings Date | Aug 03, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 70.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NVRO
Related Research
- Nevro Corp.GKOS: What does Argus have to say about GKOS?GLAUKOS CORP has an Investment Rating of HOLD; a target price of $46.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.RatingFair ValueEconomic Moat3 days agoArgus Research
- Zacks
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
- PR Newswire
Clinical Data Presented at American Diabetes Association 82nd Scientific Sessions Reinforce Significant and Durable Benefits of Nevro's HFX 10 kHz Therapy
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the results from data presentations at the American Diabetes Association (ADA) 82nd Scientific Sessions supporting the use of 10 kHz spinal cord stimulation (SCS) therapy for patients with chronic pain, including results from the SENZA Painful Diabetic Neuropathy (PDN) randomized controlled trial (RCT). Results were presented on Su
- PR Newswire
Nevro Announces SENZA-PDN Clinical Data Presentations at the American Diabetes Association 82nd Scientific Sessions
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT), the largest RCT to evaluate spinal cord stimulation (SCS) to treat PDN, will be presented at the American Diabetes Association (ADA) 82nd Scientific Sessions to be held June 3-7, 2022 in New Orleans, LA. Nevro will also showcase the compan
